Scancell (AgeTech UK) Covid-19
Oncology and Covid. Post-translational modifications, anti-glycan antibodies and cytotoxic T cels for targetting various tumours
Connections from
Investment Stage:
N/A
Funding Status:
N/A
Headquarters:
United Kingdom
Industry:
UK AgeTech 2020
Number Of Exists:
N/A
Investor Type:
N/A
Technology:
AgeTech Companies
Employee Number:
N/A
Founded Date:
N/A